课题基金 / 基金详情

DEVELOPMENT OF A NORMAL HUMAN HEPATOCYTE CELL LINE

DEVELOPMENT OF A NORMAL HUMAN HEPATOCYTE CELL LINE
正常人肝细胞系的发育
批准号:
6074632
负责人:
JING WANG
金额:
$15.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-30 至 2000-09-15

项目摘要

项目成果

JING WANG的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自研究者摘要)最初 提出,端粒酶单独可以使人类细胞永生, 对基因组的有害影响。在过去的一段时间里,这些研究人员和 其他研究人员已经证明端粒酶只能使 上皮细胞已经从MO中逃脱,这是一种端粒非依赖性的细胞, 死亡率控制参数此外,从MO的逃逸伴随着 p16/Rb肿瘤抑制通路的失活。效应器知识 MO基因(如p16基因)和端粒酶调节基因(如myc基因)的研究表明, 二元遗传组合可以显著影响单步骤 永生目前,我们缺乏一种新的技术, 用于治疗用途的细胞。调查人员已经进行了初步的 实验和建立人角质形成细胞的单步永生化。 拟议商业应用:不可用
英文摘要
DESCRIPTION: (Adapted from the Investigator's Abstract) It was initially proposed that telomerase alone could immortalize human cells without deleterious effects on the genome. In the recent past, these investigators and other researchers have demonstrated that telomerase can only immortalize epithelial cells that have already escaped from MO, a telomere-independent mortality control parameter. Furthermore, escape from MO is accompanied by inactivation of the p16/Rb tumor suppressor pathway. Knowledge of the effectors of MO (e.g. p16 gene), and of regulators of telomerase (e.g. myc) suggested that binary genetic combinations could significantly effect single-step immortalization. Currently, we lack a novel technique of immortalizing human cells for therapeutic use. The investigators have already conducted preliminary experiments and established single step immortalization of human keratinocytes. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Design of Small Molecule Antagonists of EGF-EGFR Binding
  • 批准号:
    6642618
  • 项目类别:
  • 资助金额:
    $9.97万
  • 财政年份:
    2003
  • 负责人:
    JING WANG
  • 依托单位:
海外基金